|
Chugai Pharmaceutical Co., Ltd. (4519.T) Avaliação DCF |
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Chugai Pharmaceutical Co., Ltd. (4519.T) Bundle
Obtenha informações sobre sua análise de avaliação da Chugai Pharmaceutical Co., Ltd. (4519T) com nossa sofisticada calculadora DCF! Pré -carregado com dados reais (4519T), este modelo do Excel permite ajustar as previsões e suposições para calcular com precisão o valor intrínseco da Chugai Pharmaceutical.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 786,946.0 | 999,759.0 | 1,259,946.0 | 1,111,367.0 | 1,170,611.0 | 1,307,005.1 | 1,459,291.1 | 1,629,320.8 | 1,819,161.6 | 2,031,121.8 |
| Revenue Growth, % | 0 | 27.04 | 26.02 | -11.79 | 5.33 | 11.65 | 11.65 | 11.65 | 11.65 | 11.65 |
| EBITDA | 328,724.0 | 450,301.0 | 562,660.0 | 475,644.0 | 568,388.0 | 582,462.8 | 650,328.6 | 726,101.8 | 810,703.8 | 905,163.1 |
| EBITDA, % | 41.77 | 45.04 | 44.66 | 42.8 | 48.55 | 44.56 | 44.56 | 44.56 | 44.56 | 44.56 |
| Depreciation | 30,476.0 | 30,868.0 | 31,434.0 | 31,740.0 | 26,385.0 | 38,073.1 | 42,509.1 | 47,462.1 | 52,992.2 | 59,166.6 |
| Depreciation, % | 3.87 | 3.09 | 2.49 | 2.86 | 2.25 | 2.91 | 2.91 | 2.91 | 2.91 | 2.91 |
| EBIT | 298,248.0 | 419,433.0 | 531,226.0 | 443,904.0 | 542,003.0 | 544,389.7 | 607,819.4 | 678,639.7 | 757,711.6 | 845,996.6 |
| EBIT, % | 37.9 | 41.95 | 42.16 | 39.94 | 46.3 | 41.65 | 41.65 | 41.65 | 41.65 | 41.65 |
| Total Cash | 378,620.0 | 471,970.0 | 503,107.0 | 738,982.0 | 996,345.0 | 749,850.0 | 837,219.0 | 934,767.8 | 1,043,682.5 | 1,165,287.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 253,353.0 | 356,010.0 | 512,538.0 | 318,892.0 | 334,256.0 | 433,222.6 | 483,699.7 | 540,058.1 | 602,983.1 | 673,239.9 |
| Account Receivables, % | 32.19 | 35.61 | 40.68 | 28.69 | 28.55 | 33.15 | 33.15 | 33.15 | 33.15 | 33.15 |
| Inventories | 183,893.0 | 208,838.0 | 292,206.0 | 273,480.0 | 240,067.0 | 294,243.7 | 328,527.5 | 366,806.0 | 409,544.5 | 457,262.7 |
| Inventories, % | 23.37 | 20.89 | 23.19 | 24.61 | 20.51 | 22.51 | 22.51 | 22.51 | 22.51 | 22.51 |
| Accounts Payable | 100,396.0 | 152,266.0 | 209,835.0 | 54,234.0 | 65,353.0 | 144,045.0 | 160,828.4 | 179,567.4 | 200,489.7 | 223,849.8 |
| Accounts Payable, % | 12.76 | 15.23 | 16.65 | 4.88 | 5.58 | 11.02 | 11.02 | 11.02 | 11.02 | 11.02 |
| Capital Expenditure | -61,411.0 | -72,866.0 | -71,239.0 | -74,258.0 | -50,925.0 | -83,068.5 | -92,747.2 | -103,553.7 | -115,619.3 | -129,090.7 |
| Capital Expenditure, % | -7.8 | -7.29 | -5.65 | -6.68 | -4.35 | -6.36 | -6.36 | -6.36 | -6.36 | -6.36 |
| Tax Rate, % | 28.68 | 28.68 | 28.68 | 28.68 | 28.68 | 28.68 | 28.68 | 28.68 | 28.68 | 28.68 |
| EBITAT | 214,776.2 | 303,029.7 | 374,471.3 | 325,532.9 | 386,581.6 | 391,319.0 | 436,913.6 | 487,820.7 | 544,659.3 | 608,120.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -153,008.8 | 185,299.7 | 152,339.3 | 339,785.9 | 391,209.6 | 271,872.2 | 318,698.0 | 355,831.2 | 397,291.0 | 443,581.5 |
| WACC, % | 6.64 | 6.64 | 6.64 | 6.64 | 6.64 | 6.64 | 6.64 | 6.64 | 6.64 | 6.64 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1,457,503.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 452,453 | |||||||||
| Terminal Value | 9,753,667 | |||||||||
| Present Terminal Value | 7,072,805 | |||||||||
| Enterprise Value | 8,530,308 | |||||||||
| Net Debt | -540,202 | |||||||||
| Equity Value | 9,070,510 | |||||||||
| Diluted Shares Outstanding, MM | 1,646 | |||||||||
| Equity Value Per Share | 5,511.85 |
What You Will Receive
- Customizable Excel Template: A fully editable Excel-based DCF Calculator featuring pre-filled real financial data for Chugai Pharmaceutical Co., Ltd. (4519T).
- Authentic Data: Access to historical performance metrics and forward-looking projections (highlighted in the yellow cells).
- Flexible Forecasting: Adjust key assumptions such as revenue growth, EBITDA margin, and WACC to suit your analysis.
- Real-Time Calculations: Immediately observe how your input changes influence Chugai's valuation.
- Professional-Grade Tool: Designed for use by investors, CFOs, consultants, and financial analysts.
- Intuitive Design: Organized for simplicity and ease of navigation, accompanied by step-by-step guidance.
Key Features
- 🔍 Real-Life Chugai Pharmaceutical Financials: Pre-filled historical and projected data for Chugai Pharmaceutical Co., Ltd. (4519T).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) such as WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Integrated formulas calculate Chugai’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Chugai’s valuation instantly after making adjustments.
- Scenario Analysis: Evaluate and compare results for different financial assumptions side-by-side.
How It Functions
- Step 1: Download the Excel file.
- Step 2: Examine the pre-filled Chugai Pharmaceutical data (historical and projected).
- Step 3: Modify key assumptions (highlighted in yellow) according to your analysis.
- Step 4: Observe automatic recalculations for Chugai Pharmaceutical’s intrinsic value.
- Step 5: Utilize the results for investment strategies or reporting purposes.
Why Choose This Investment Calculator for Chugai Pharmaceutical Co., Ltd. (4519T)?
- Data Integrity: Utilizes accurate financial records from Chugai Pharmaceutical to ensure reliable outcomes.
- Customizable: Built to allow users to effortlessly test and adjust various inputs.
- Efficiency: Eliminate the complexity of constructing a discounted cash flow (DCF) model independently.
- Expert-Level Design: Crafted to meet the standards of professionals with CFO-level functionality and user experience.
- Accessible: Intuitive interface designed for all users, regardless of their financial modeling expertise.
Who Can Benefit from This Product?
- Institutional Investors: Develop comprehensive and accurate valuation models for assessing portfolios involving Chugai Pharmaceutical Co., Ltd. (4519T).
- Corporate Finance Departments: Evaluate valuation scenarios to inform strategic decisions within their organizations.
- Consultants and Financial Advisors: Deliver precise valuation insights related to Chugai Pharmaceutical Co., Ltd. (4519T) for their clients.
- Academics and Students: Utilize real-world data to enhance learning and practice in financial modeling.
- Pharmaceutical Enthusiasts: Gain insights into how companies like Chugai Pharmaceutical Co., Ltd. (4519T) are valued in the industry.
Contents of the Template
- Pre-Populated Data: Contains Chugai Pharmaceutical’s historical financial figures and projections.
- Discounted Cash Flow Model: Interactive DCF valuation model featuring automated calculations.
- Weighted Average Cost of Capital (WACC): A specific sheet for computing WACC using customized inputs.
- Essential Financial Ratios: Evaluate Chugai’s profitability, efficiency, and financial leverage.
- Customizable Variables: Easily modify revenue growth rates, profit margins, and tax rates.
- User-Friendly Dashboard: Visuals and tables that encapsulate key valuation outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.